ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy

References

• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen, patient-level meta-analysis of randomised trialsLancet2011378979377178421802721
   PubMed Web of Science ®Google Scholar
• DaviesCPanHGodwinJAdjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative GroupLong-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positivebreast cancer: ATLAS, a randomised trialLancet2013381986980581623219286
   PubMed Web of Science ®Google Scholar
• BursteinHJTeminSAndersonHAdjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused updateJ Clin Oncol201432212255226924868023
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNPritchardKIExtending aromatase-inhibitor adjuvant therapy to 10 yearsN Engl J Med2016375320921927264120
   PubMed Web of Science ®Google Scholar
• BlowsFMDriverKESchmidtMKSubtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studiesPLoS Med201075e100027920520800
   PubMed Web of Science ®Google Scholar
• FisherBDignamJBryantJWolmarkNFive versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trialJ Natl Cancer Inst200193968469011333290
   PubMed Web of Science ®Google Scholar
• HowellACuzickJBaumMATAC Trialists’ GroupResults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancerLancet20053659453607215639680
   PubMed Web of Science ®Google Scholar
• MauriacLKeshaviahADebledMBIG 1-98 Collaborative GroupInternational Breast Cancer Study GroupPredictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trialAnn Oncol200718585986717301074
   PubMed Web of Science ®Google Scholar
• DowsettMAllredCKnoxJRelationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trialJ Clin Oncol20082671059106518227529
   PubMed Web of Science ®Google Scholar
• DugganCMarriottKEdwardsRCuzickJInherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancerJ Clin Oncol200321193588359314512389
   PubMedGoogle Scholar
• FornanderTRutgvistLECedermarkBAdjuvant tamoxifen in early breast cancer: occurrence of new primary cancersLancet1989186301171202563046
   PubMed Web of Science ®Google Scholar
• BaumMBudzarAUCuzickJATAC Trialists’ GroupAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialLancet200235993242131213912090977
   PubMed Web of Science ®Google Scholar
• KoboldtDCFultonRSMcLellanMDCancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• LiJJiangYLiuYShaoZIdentify high risk estrogen receptor-positive breast cancer patients for extended endocrine therapyBreast20173117318027866092
   PubMedGoogle Scholar
• CheangMCChiaSKVoducDKi67 index, HER2 status, and prognosis of patients with luminal B breast cancerJ Natl Cancer Inst20091011073675019436038
   PubMed Web of Science ®Google Scholar
• ElstonCWEllisIOPathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-upHistopathology19911954034101757079
   PubMed Web of Science ®Google Scholar
• CoatesASWinerEPGoldhirschAPanel MembersTailoring therapies-improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015Ann Oncol20152681533154625939896
   PubMed Web of Science ®Google Scholar
• SestakIDowsettMZabagloLFactors predicting late recurrence for estrogen receptor-positive breast cancerJ Natl Cancer Inst2013105191504151124029245
   PubMedGoogle Scholar
• KenneckeHFOlivottoIASpeersCLate risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifenAnn Oncol2007181455117030545
   PubMed Web of Science ®Google Scholar
• HongchaoPanGray RichardGChristinaDaviesFor the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Predictors of recurrence during years 5–14 in 46,138 women with ER + breast cancer allocated 5 years only of endocrine therapy (ET). Poster presented at: Annual meeting ASCO; 2016J Clin Oncol34suppl abstr 505
   Google Scholar
• de AzambujaECardosoFde CastroGJrKi-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patientsBr J Cancer200796101504151317453008
   PubMed Web of Science ®Google Scholar
• CreightonCJKent OsborneCvan de VijverMJMolecular profiles of progesterone receptor loss in human breast tumorsBreast Cancer Res Treat2009114228729918425577
   PubMed Web of Science ®Google Scholar
• JinihMRelihanNCorriganMAO’ReillySRedmondHPExtended adjuvant endocrine therapy in breast cancer: evidence and update – a reviewBreast J Epub201732
   PubMedGoogle Scholar
• SgroiDCSestakICuzickJPrediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study populationLancet Oncol201314111067107624035531
   PubMed Web of Science ®Google Scholar
• ZhangYSchnabelCASchroederBEBreast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrenceClin Cancer Res201319154196420523757354
   PubMed Web of Science ®Google Scholar
• HarrisLNIsmailaNMcShaneLMUse of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guidelineJ Clin Oncol201634101134115026858339
   PubMed Web of Science ®Google Scholar